Tell Ulcerative Colitis Patients Entyvio Doesn't Seem to Cause Immunosuppression

Entyvio (en-TIH-vee-oh, vedolizumab) is a new biologic option for treating ulcerative colitis in adults.

It's also approved for treating Crohn's disease in the U.S. and Europe...but not yet in Canada.

Entyvio is an integrin inhibitor...similar to Tysabri (natalizumab) for multiple sclerosis. But Entyvio is selective for the gut.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote